Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Clinical activity of sorafenib in a previously treated advanced urothelial cancer patient.

Shah CH, Viktorsson K, Sherif A, Kanter L, Grybäck P, Lewensohn R, Sandström P, Nilsson S, Ullén A.

Anticancer Drugs. 2013 Jul;24(6):648-52. doi: 10.1097/CAD.0b013e328360c1c3.

PMID:
23542751
2.

Pituitary metastasis from a renal cell carcinoma progressed after sorafenib treatment.

Yang L, Yu SY, Hu GY.

Chin J Cancer. 2013 Jun;32(6):353-6. doi: 10.5732/cjc.012.10184. Epub 2012 Dec 7.

3.

Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group.

Tafreshi A, Thientosapol E, Liew MS, Guo Y, Quaggiotto M, Boyer M, Davis ID.

Asia Pac J Clin Oncol. 2014 Mar;10(1):60-5. doi: 10.1111/ajco.12122. Epub 2013 Oct 24.

PMID:
24152417
4.

Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study.

Kim SH, Kim S, Nam BH, Lee SE, Kim CS, Seo IY, Kim TN, Hong SH, Kwon TG, Seo SI, Joo KJ, Song K, Kwak C, Chung J.

PLoS One. 2015 Aug 26;10(8):e0135165. doi: 10.1371/journal.pone.0135165. eCollection 2015.

5.

Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study.

Jäger D, Ma JH, Mardiak J, Ye DW, Korbenfeld E, Zemanova M, Ahn H, Guo J, Leonhartsberger N, Stauch K, Böckenhoff A, Yu J, Escudier B.

Clin Genitourin Cancer. 2015 Apr;13(2):156-64.e1. doi: 10.1016/j.clgc.2014.07.007. Epub 2014 Aug 23.

6.

Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.

Hittinger M, Staehler M, Schramm N, Ubleis C, Becker C, Reiser M, Berger F.

Urol Oncol. 2012 Sep;30(5):695-703. doi: 10.1016/j.urolonc.2010.10.011. Epub 2011 Aug 24.

PMID:
21865061
7.

Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.

Kusuda Y, Miyake H, Behnsawy HM, Fukuhara T, Inoue TA, Fujisawa M.

Urol Oncol. 2013 Jan;31(1):42-50. doi: 10.1016/j.urolonc.2010.09.008. Epub 2011 Mar 10.

PMID:
21396851
8.

Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib.

Kondo T, Nakazawa H, Oya M, Kimura G, Fujii Y, Hatano T, Kawata N, Kume H, Morita M, Nakajima K, Ohno Y, Okegawa T, Takahashi S, Wakumoto Y, Horie S, Yamaguchi R, Saito K, Murakami M.

Jpn J Clin Oncol. 2015 Mar;45(3):274-80. doi: 10.1093/jjco/hyu200. Epub 2014 Nov 23.

PMID:
25420693
9.

Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.

Grenader T, Rosenbaum E, Zilber S, Bogot N, Shavit L.

Clin Genitourin Cancer. 2013 Jun;11(2):201-3. doi: 10.1016/j.clgc.2012.11.005. Epub 2012 Dec 23. No abstract available.

PMID:
23266054
10.

Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.

Nakano K, Komatsu K, Kubo T, Natsui S, Nukui A, Kurokawa S, Kobayashi M, Morita T.

Jpn J Clin Oncol. 2013 Oct;43(10):1023-9. doi: 10.1093/jjco/hyt110. Epub 2013 Aug 15.

PMID:
23956442
11.

[Drug now immediately available in Germany].

[No authors listed]

Aktuelle Urol. 2006 Sep;37(5 Suppl):18-9. German. No abstract available.

PMID:
23646396
12.

Efficacy and safety of sorafenib in advanced renal cell cancer and validation of Heng criteria.

Joshi A, Ramaswamy A, Noronha V, Patil VM, Chandrasekharan A, Goel A, Sahu A, Sable N, Agrawal A, Menon S, Prabhash K.

Indian J Cancer. 2016 Jul-Sep;53(3):423-428. doi: 10.4103/0019-509X.200662.

13.

Relationship of pathologic factors to efficacy of sorafenib treatment in patients with metastatic clear cell renal cell carcinoma.

Araki H, Tsuzuki T, Kimura T, Tanaka K, Yamada S, Sassa N, Yoshino Y, Hattori R, Gotoh M.

Am J Clin Pathol. 2015 Apr;143(4):492-9. doi: 10.1309/AJCPM8RJ2ECAWOGQ.

PMID:
25780000
14.

Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma.

Erös de Bethlenfalva-Hora C, Mertens JC, Piguet AC, Kettenbach J, Schmitt J, Terracciano L, Weimann R, Dufour JF, Geier A.

Clin Sci (Lond). 2014 Feb;126(3):243-52. doi: 10.1042/CS20130089.

PMID:
23822114
15.

Sorafenib in renal cell carcinoma.

Davoudi ET, bin-Noordin MI, Javar HA, Kadivar A, Sabeti B.

Pak J Pharm Sci. 2014 Jan;27(1):203-8. Review.

PMID:
24374450
16.

[Side effects of sorafenib and countermeasures].

Nakayama M, Arai Y, Nishimura K.

Hinyokika Kiyo. 2012 Nov;58(11):635-7. Japanese.

17.

Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.

Smolle E, Taucher V, Petru E, Haybaeck J.

Anticancer Res. 2014 Apr;34(4):1519-30. Review.

PMID:
24692678
18.

Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.

Mancuso A, Di Paola ED, Leone A, Catalano A, Calabrò F, Cerbone L, Zivi A, Messina C, Alonso S, Vigna L, Caristo R, Sternberg CN.

BJU Int. 2012 Jan;109(2):200-6. doi: 10.1111/j.1464-410X.2011.10421.x.

19.

Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis.

Larkin J, Paine A, Tumur I, Cappelleri JC, Healey PJ Sr, Foley G, Mitchell S, Kroes M, Chen C.

Expert Opin Pharmacother. 2013 Jan;14(1):27-39. doi: 10.1517/14656566.2013.758713. Epub 2012 Dec 21. Review.

PMID:
23256638
20.

Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies.

Antoun S, Lanoy E, Iacovelli R, Albiges-Sauvin L, Loriot Y, Merad-Taoufik M, Fizazi K, di Palma M, Baracos VE, Escudier B.

Cancer. 2013 Sep 15;119(18):3377-84. doi: 10.1002/cncr.28218. Epub 2013 Jun 25.

Supplemental Content

Support Center